Gibson, Dunn & Crutcher LLP has advised X4 Pharmaceuticals, and Freshfields US LLP has advised the underwriters. Dechert LLP has served as special counsel for X4...
You must be a Standard 1 Year member to access this content.
Gibson Dunn has advised XOMA Royalty Corporation, and Duane Morris has advised H.C. Wainwright & Co., LLC. XOMA Royalty Corporation has established an at-the-market facility allowing...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher has advised XOMA Royalty Corporation, and Duane Morris LLP has advised Leerink Partners LLC. XOMA Royalty Corporation has established two at-the-market facilities,...
You must be a Standard 1 Year member to access this content.
Sidley Austin has advised Roche, and Gibson, Dunn & Crutcher LLP has advised 89bio, Inc. Roche has entered into a definitive merger agreement to acquire 89bio,...
You must be a Standard 1 Year member to access this content.
Gibson Dunn and Goodwin Procter has advised Dianthus Therapeutics, Inc., while Cooley has represented the underwriters. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on antibody...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher advised Spyre Therapeutics, Inc. on the offering, and Covington & Burling advised the underwriters. Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised 89bio, Inc. on the offering, and Cooley advised the underwriters. 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising ARCA biopharma, Inc. on the transaction, while Gibson, Dunn & Crutcher is advising Oruka Therapeutics and Cooley is advising...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher represented Apogee Therapeutics, Inc. in the offering, and Cooley represented the underwriters. Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company, announced the...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP represented Dianthus Therapeutics, Inc. on the placement. Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation...
You must be a Standard 1 Year member to access this content.
